marked.bio

Company

Jiangsu Aosaikang Pharmaceutical

5 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

limertinib 3osimertinib 1

Trials

5 of 7 trials shown

  1. ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

    Not yet recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2026Primary completion 2030-12 NCT07897188

    ASKC202ASKC202 placeboosimertinib FDA EUpemetrexedcisplatincarboplatinlimertinib

    The tumor harbors EGFR sensitizing mutation (Ex19Del or L858R).

    EGFR exon 19 deletion / L858REGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive

  2. ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

    Recruiting Phase 3 Jiangsu Aosaikang Pharmaceutical Started 2025Primary completion 2027-10 NCT07109531

    limertinibpemetrexedcisplatincarboplatin

    EGFR mutation with MET amplification/Overexpression by a central laboratory;

    EGFR exon 19 deletion / L858RLocally Advanced or Metastatic NSCLC

  3. A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

    Active, not recruiting Phase 1/2 Jiangsu Aosaikang Pharmaceutical Started 2021Primary completion 2025-10 NCT04632108

    ASKB589 Injection

    …have no access to standard therapy for various reasons, and that tumor tissue samples are CLDN18.2 positive detected by central laboratory (medium-high expression)；

    Claudin 18.2 expressionMalignant Solid Tumor

  4. Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

    Not yet recruiting Phase 1 Jiangsu Aosaikang Pharmaceutical Started 2026Primary completion 2028-11 NCT07836036

    ASKC189

    Documentation of KRAS/NRAS/HRAS mutation determined by validated local testing of tumor tissue or circulating free DNA (cfDNA) in …

    KRAS G12CKRAS G12DSolid Tumor, RAS Mutation

  5. Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

    Recruiting Phase 1 Jiangsu Aosaikang Pharmaceutical Started 2022Primary completion 2026-12 NCT05306132

    ASKC202limertinib

    …ocally advanced or metastatic NSCLC;b)Histologically confirmed EGFR sensitizing mutation (Ex19del or L858R).；c)Disease progression following treatment with a third-generation EGFR TKI, or…

    EGFR exon 19 deletion / L858RAdvanced Solid Tumor